The Experts below are selected from a list of 27 Experts worldwide ranked by ideXlab platform

Ravindra Mohan Pandey - One of the best experts on this subject based on the ideXlab platform.

  • anti saccharomyces Cerevisiae Antibody does not differentiate between crohn s disease and intestinal tuberculosis
    Digestive Diseases and Sciences, 2007
    Co-Authors: Govind K Makharia, Vikas Sachdev, Rajiva Gupta, Suman Lal, Ravindra Mohan Pandey
    Abstract:

    The clinical, morphological, and histological features of intestinal tuberculosis (IT) and Crohn's disease (CD) mimic so much, that it becomes difficult to differentiate between them. The sensitivity of Anti-Saccharomyces Cerevisiae Antibody (ASCA) IgG and ASCA IgA in CD is 60%–80%, whereas the specificity is almost 90%. There are no reports of study of ASCA in patients with IT, nor has it ever been used to differentiate CD from IT. Patients with ulcerative colitis (UC; n=25), CD (n=59), and IT (n=30) and 21 healthy controls were included in this study. The location and behavior of CD were classified according to the Modified Montreal classification. Five milliliters of blood was taken from them and serum was stored at −70°C. ASCA antibodies (both IgG and IgA) were estimated using commercially available ELISA kits (AESKU Diagnostics, Germany). Anti-neutrophilic cytoplasmic Antibody was measured by indirect immunoflorescence test. ASCA IgA was positive in 4.7%, 28%, 33.9%, and 43.3% and ASCA IgG was positive in 4.7%, 24%, 50.8%, and 46.6% of healthy controls and patients with UC, CD, and IT, respectively. Either ASCA IgG or ASCA IgA was positive in 9.5%, 40%, 61% and 66.6% of healthy controls, UC, CD, and IT, respectively. ANCA was positive in 0%, 32%, 10.1%, and 6.6% of healthy controls, UC, CD, and IT, respectively. ASCA IgG was positive in a significantly higher number of patients with CD (P<0.0001) and IT (P<0.0001) in comparison to healthy controls. ASCA IgA was positive in a significantly higher number of patients with UC (P<0.04), CD (P<0.013), and IT (P<0.006) in comparison to healthy controls. In comparisons between diseases, ASCA IgG was positive in significantly more patients with CD (P<0.001) and IT (P<0.001) in comparison to UC. There was no significant difference in ASCA IgA (33.9% vs. 43.3%), ASCA IgG (50.86% vs. 46.6%), or ANCA (10.7%, 7.4%) in patients with CD and IT, respectively. There was no correlation between ASCA and duration, location and behavior of CD, and IT. We conclude that ASCA IgG and ASCA IgA do not help to differentiate between IT and CD.

Govind K Makharia - One of the best experts on this subject based on the ideXlab platform.

  • anti saccharomyces Cerevisiae Antibody does not differentiate between crohn s disease and intestinal tuberculosis
    Digestive Diseases and Sciences, 2007
    Co-Authors: Govind K Makharia, Vikas Sachdev, Rajiva Gupta, Suman Lal, Ravindra Mohan Pandey
    Abstract:

    The clinical, morphological, and histological features of intestinal tuberculosis (IT) and Crohn's disease (CD) mimic so much, that it becomes difficult to differentiate between them. The sensitivity of Anti-Saccharomyces Cerevisiae Antibody (ASCA) IgG and ASCA IgA in CD is 60%–80%, whereas the specificity is almost 90%. There are no reports of study of ASCA in patients with IT, nor has it ever been used to differentiate CD from IT. Patients with ulcerative colitis (UC; n=25), CD (n=59), and IT (n=30) and 21 healthy controls were included in this study. The location and behavior of CD were classified according to the Modified Montreal classification. Five milliliters of blood was taken from them and serum was stored at −70°C. ASCA antibodies (both IgG and IgA) were estimated using commercially available ELISA kits (AESKU Diagnostics, Germany). Anti-neutrophilic cytoplasmic Antibody was measured by indirect immunoflorescence test. ASCA IgA was positive in 4.7%, 28%, 33.9%, and 43.3% and ASCA IgG was positive in 4.7%, 24%, 50.8%, and 46.6% of healthy controls and patients with UC, CD, and IT, respectively. Either ASCA IgG or ASCA IgA was positive in 9.5%, 40%, 61% and 66.6% of healthy controls, UC, CD, and IT, respectively. ANCA was positive in 0%, 32%, 10.1%, and 6.6% of healthy controls, UC, CD, and IT, respectively. ASCA IgG was positive in a significantly higher number of patients with CD (P<0.0001) and IT (P<0.0001) in comparison to healthy controls. ASCA IgA was positive in a significantly higher number of patients with UC (P<0.04), CD (P<0.013), and IT (P<0.006) in comparison to healthy controls. In comparisons between diseases, ASCA IgG was positive in significantly more patients with CD (P<0.001) and IT (P<0.001) in comparison to UC. There was no significant difference in ASCA IgA (33.9% vs. 43.3%), ASCA IgG (50.86% vs. 46.6%), or ANCA (10.7%, 7.4%) in patients with CD and IT, respectively. There was no correlation between ASCA and duration, location and behavior of CD, and IT. We conclude that ASCA IgG and ASCA IgA do not help to differentiate between IT and CD.

Jae Hee Cheon - One of the best experts on this subject based on the ideXlab platform.

  • diagnostic utility of anti saccharomyces Cerevisiae Antibody asca and interferon assay in the differential diagnosis of crohn s disease and intestinal tuberculosis
    Clinica Chimica Acta, 2011
    Co-Authors: You Sun Kim, Young Ho Kim, Won Ho Kim, Joo Sung Kim, Young Sook Park, Suk Kyun Yang, Byung Ik Jang, Sung Ae Jung, Yoon Tae Jeen, Jae Hee Cheon
    Abstract:

    Abstract Background Differential diagnosis of Crohn's disease (CD) from intestinal tuberculosis (ITB) is challenging. Anti- Saccharomyces Cerevisiae Antibody (ASCA) is a specific serological marker for CD and INF-gamma assay (QuantiFERON-TB gold test, QFT) is a good supplementary diagnostic tool for ITB. We evaluated the clinical usefulness of ASCA and QFT for differential diagnosis of CD from ITB in Korean adults. Methods A total of 147 patients suspected to have ITB or CD were prospectively enrolled from 13 hospitals. ASCA IgG and IgA serum titers were measured by ELISA, and the QFT test was also performed. Results Thirty-two of 72 (44.4%) patients with CD were ASCA positive (titer > 25 U) compared to 10 of 75 ITB patients (13.3%) and 3 of 20 healthy controls (15%) ( p p Conclusion ASCA is a useful diagnostic tool for CD in Korea, where ITB is prevalent. In particular, when ASCA is combined with QFT, effective differential diagnosis of CD from ITB is possible.

Joseph J Y Sung - One of the best experts on this subject based on the ideXlab platform.

  • systematic review with meta analysis accuracy of interferon gamma releasing assay and anti saccharomyces Cerevisiae Antibody in differentiating intestinal tuberculosis from crohn s disease in asians
    Journal of Gastroenterology and Hepatology, 2014
    Co-Authors: Hoyee W Hirai, Kelvin K F Tsoi, Sunny H Wong, Francis K L Chan, Joseph J Y Sung
    Abstract:

    Background and Aims Distinguishing Crohn's disease (CD) from intestinal tuberculosis (ITB) is a clinical challenge. This meta-analysis assessed the clinical usefulness of Interferon-gamma releasing assay (IGRA) and Anti-Saccharomyces Cerevisiae Antibody (ASCA) in the diagnosis of ITB and CD, respectively. Methods Systematic search without language restriction was conducted in AMED, EBM, MEDLINE, EMBASE, and Google Scholar until September 2013. Studies that have evaluated performance of IGRA (QuantiFERON-TB Gold or T-SPOT.TB) or ASCA in distinguishing ITB from CD were eligible. Main outcome measures included sensitivity and specificity. Random-effects models were used to combine estimates from studies with significant heterogeneity. Area under the curve (AUC) was used to measure accuracy of the tests. Results Eleven studies (five IGRA, three ASCA, three IGRA and ASCA) involving 1081 subjects were included. The pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of IGRA for the diagnosis of ITB was 81% (95% CI, 75–86%), 85% (95% CI, 81–89%), 6.02 (95% CI: 4.62–7.83), and 0.19 (95% CI: 0.10–0.36), respectively. The AUC was 0.92. The pooled sensitivity and specificity of ASCA for the diagnosis of CD was 33% (95% confidence interval [CI], 27%–38%) and 83% (95% CI, 77–88%), respectively with an AUC of 0.58. T-SPOT.TB showed a higher sensitivity than QuantiFERON-TB Gold for the diagnosis of ITB. Conclusions IGRA and ASCA have a high specificity for the diagnosis of ITB. Both IGRA and ASCA may have a supplementary role in the differential diagnosis between ITB and CD when conventional workup is not diagnostic.

Rajiva Gupta - One of the best experts on this subject based on the ideXlab platform.

  • anti saccharomyces Cerevisiae Antibody does not differentiate between crohn s disease and intestinal tuberculosis
    Digestive Diseases and Sciences, 2007
    Co-Authors: Govind K Makharia, Vikas Sachdev, Rajiva Gupta, Suman Lal, Ravindra Mohan Pandey
    Abstract:

    The clinical, morphological, and histological features of intestinal tuberculosis (IT) and Crohn's disease (CD) mimic so much, that it becomes difficult to differentiate between them. The sensitivity of Anti-Saccharomyces Cerevisiae Antibody (ASCA) IgG and ASCA IgA in CD is 60%–80%, whereas the specificity is almost 90%. There are no reports of study of ASCA in patients with IT, nor has it ever been used to differentiate CD from IT. Patients with ulcerative colitis (UC; n=25), CD (n=59), and IT (n=30) and 21 healthy controls were included in this study. The location and behavior of CD were classified according to the Modified Montreal classification. Five milliliters of blood was taken from them and serum was stored at −70°C. ASCA antibodies (both IgG and IgA) were estimated using commercially available ELISA kits (AESKU Diagnostics, Germany). Anti-neutrophilic cytoplasmic Antibody was measured by indirect immunoflorescence test. ASCA IgA was positive in 4.7%, 28%, 33.9%, and 43.3% and ASCA IgG was positive in 4.7%, 24%, 50.8%, and 46.6% of healthy controls and patients with UC, CD, and IT, respectively. Either ASCA IgG or ASCA IgA was positive in 9.5%, 40%, 61% and 66.6% of healthy controls, UC, CD, and IT, respectively. ANCA was positive in 0%, 32%, 10.1%, and 6.6% of healthy controls, UC, CD, and IT, respectively. ASCA IgG was positive in a significantly higher number of patients with CD (P<0.0001) and IT (P<0.0001) in comparison to healthy controls. ASCA IgA was positive in a significantly higher number of patients with UC (P<0.04), CD (P<0.013), and IT (P<0.006) in comparison to healthy controls. In comparisons between diseases, ASCA IgG was positive in significantly more patients with CD (P<0.001) and IT (P<0.001) in comparison to UC. There was no significant difference in ASCA IgA (33.9% vs. 43.3%), ASCA IgG (50.86% vs. 46.6%), or ANCA (10.7%, 7.4%) in patients with CD and IT, respectively. There was no correlation between ASCA and duration, location and behavior of CD, and IT. We conclude that ASCA IgG and ASCA IgA do not help to differentiate between IT and CD.